Cantor Fitzgerald Cuts Pharvaris (NASDAQ:PHVS) Price Target to $25.00

Pharvaris (NASDAQ:PHVS) had its price target lowered by Cantor Fitzgerald from $28.00 to $25.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Pharvaris’ FY2025 earnings at ($3.41) EPS.

Separately, JMP Securities increased their target price on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Stock Performance

PHVS stock opened at $16.56 on Wednesday. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $25.50. The business’s 50-day moving average is $15.38 and its two-hundred day moving average is $17.68. The company has a market cap of $865.92 million, a price-to-earnings ratio of -5.91 and a beta of -2.85.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.09). Equities analysts predict that Pharvaris will post -2.71 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its position in shares of Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after buying an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Pharvaris during the 4th quarter valued at about $64,000. Barclays PLC purchased a new position in shares of Pharvaris during the 3rd quarter valued at about $106,000. KLP Kapitalforvaltning AS purchased a new position in shares of Pharvaris during the 4th quarter valued at about $111,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Pharvaris during the 4th quarter valued at about $152,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.